NCT05489718View on ClinicalTrials.gov

A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

June 5, 2023

Study Completion Date

June 5, 2023

Conditions
Diabetic Macular Edema
Interventions
BIOLOGICAL

IBI324

Dose 2 IBI324 of multiple IVT injection

BIOLOGICAL

IBI324

Dose 2 IBI324 of single IVT injection

BIOLOGICAL

IBI324

Dose 1 IBI324 of single IVT injection

BIOLOGICAL

IBI324

Dose 3 IBI324 of single IVT injection

BIOLOGICAL

IBI324

Dose 3 IBI324 of multiple IVT injection

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY